BiotechTube

Zinforo (ceftaroline fosamil)

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Community Acquired Pneumonia

Conditions

Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection

Trial Timeline

May 17, 2020 → Aug 30, 2021

NCT ID
NCT04198571

About Zinforo (ceftaroline fosamil)

Zinforo (ceftaroline fosamil) is a pre-clinical stage product being developed by Pfizer for Community Acquired Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT04198571. Target conditions include Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection.

What happened to similar drugs?

2 of 13 similar drugs in Community Acquired Pneumonia were approved

Approved (2) Terminated (2) Active (9)
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
✅TelithromycinSanofiApproved
🔄Ceftaroline + CeftriaxonePfizerPhase 3
🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3
🔄tigecyclinePfizerPhase 3
🔄Azithromycin SRPfizerPhase 3
❌Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04198571Pre-clinicalCompleted

Competing Products

17 competing products in Community Acquired Pneumonia

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
27
Ceftaroline + CeftriaxonePfizerPhase 3
40
Azithromycin microspheres 2.0 single dosePfizerPhase 3
40
tigecyclinePfizerPhase 3
40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
43
Azithromycin SRPfizerPhase 3
40
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3
32
Azithromycin SR + AmoxiclavPfizerPre-clinical
18
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3
32
tigecyclinePfizerPhase 3
40
Tigecycline + LevofloxacinPfizerPhase 3
40
AzithromycinPfizerPhase 3
40
TelithromycinSanofiApproved
43
Omadacycline + MoxifloxacinZai LabPhase 3
41
ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3
34
EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 daysEnanta PharmaceuticalsPhase 2
21